GlyProVac has via its proprietary platform technology, BEMAP, discovered that 1) O-linked protein glycosylation is a surprisingly abundant post translational modification in bacterial, 2) glycoproteins are linked to increased immunogenicity.
GlyProVac aim to be the first to explore and exploit this novel class of antigens as candidates for vaccine development. The GlyProVac lead YghJ/SslE/AcfD is a conserved protein with a known biological function and has vaccine potential not only in ETEC but also in UPEC. Using BEMAP, GlyProVac has identified 59 glycosylated residues in YghJ. We are in the PoC phase and currently work to establish that glycosylated YghJ elicit a more protective immune response compared to the non-glycosylated version.
Company Details
- Employees
- 12
- Founded
- 2018
- Address
- Odense, Fyn 5230, Dk
- bo****@****Vac.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- glyprovac.com
- HQ
- Odense, Fyn
Glyprovac Questions
Glyprovac's website is glyprovac.com
Glyprovac's LinkedIn profile is https://dk.linkedin.com/company/glyprovac
Glyprovac has
12 employees.
View email and phone details for 12
employees at Glyprovac.
Glyprovac's industry is
Biotechnology Research
Glyprovac's top competitors are
Serendip Innovations,
Phoenestra Gmbh,
Ampliqon A/s,
Ikarovec,
Theriva Biologics, Inc.,
Fuse Vectors,
Atlyphe Ag,
Gene Vector,
Amplexa Genetics A/s,
Liberabio.
Glyprovac's support email address is boysen@GlyProVac.com
Glyprovac's categories are Biotechnology Research
Glyprovac's founding year is 2018
